Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study ; volume:8 ; number:1 ; day:3 ; month:4 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (3.4.2018), 1-11, 12.2018
- Urheber
-
Bazin, Thomas
- Beteiligte Personen und Organisationen
-
Hooks, Katarzyna B.
Barnetche, Thomas
Truchetet, Marie-Elise
Enaud, Raphaël
Richez, Christophe
Dougados, Maxime
Hubert, Christophe
Barré, Aurélien
Nikolski, Macha
Schaeverbeke, Thierry
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-23571-4
- URN
-
urn:nbn:de:1111-201805288852
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bazin, Thomas
- Hooks, Katarzyna B.
- Barnetche, Thomas
- Truchetet, Marie-Elise
- Enaud, Raphaël
- Richez, Christophe
- Dougados, Maxime
- Hubert, Christophe
- Barré, Aurélien
- Nikolski, Macha
- Schaeverbeke, Thierry
- SpringerLink (Online service)
Ähnliche Objekte (12)
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases
Monitoring of anti-TNF biological treatments
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases
Monitoring of anti-TNF biological treatments
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases
Monitoring of anti-TNF biological treatments
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy